Evidence map›Paper›PMID 24009514›Full record

Trial reportPLoS pathogens2013

Intact type I Interferon production and IRF7 function in sooty mangabeys.

Steven E Bosinger, Zachary P Johnson, Kathryn A Folkner, Nirav Patel, Tayebeh Hashempour, Simon P Jochems, Perla M Del Rio Estrada, Mirko Paiardini, Rongtuan Lin, Thomas H Vanderford and 2 more

Open access · goldAbstract readClinical Trial
In one paragraph

Trial report in PLoS pathogens, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
7.2field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 35 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Review
  17. Review
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 2 countries.

Steven E BosingerDivison of Microbiology and Immunology, Emory Vaccine Center, Yerkes National Primate Research Center, Atlanta, Georgia, United States of America. sbosing@emory.edu
Zachary P Johnson
Kathryn A Folkner
Nirav Patel
Tayebeh Hashempour
Simon P Jochems
Perla M Del Rio Estrada
Mirko Paiardini
Rongtuan Lin
Thomas H Vanderford
John Hiscott
Guido Silvestri
Emory National Primate Research CenterEmory University · USJewish General Hospital · CAMcGill University · CA

Funding

National Institute on Aging (NIA) ColonyP51OD011107 · OD · UNIVERSITY OF CALIFORNIA AT DAVIS · PI Simon J. Atkinson · 2012 to 2026
$191.5M
STUDIES OF NATURAL SIV INFECTION OF SOOTY MANGABEYSR37AI066998 · NIAID · EMORY UNIVERSITY · PI SILVESTRI, GUIDO · 2011 to 2020
$7.7M
CCR NIH HHS HHSN261200800001CNCI NIH HHS HHSN261200800001ENCRR NIH HHS P51RR169NIAID NIH HHS R37 AI066998NIAID NIH HHS R37AI66998NIH HHS P51 OD011107NIH HHS P51OD11107
6 · The paper itself

Abstract

In contrast to pathogenic HIV/SIV infections of humans and rhesus macaques (RMs), natural SIV infection of sooty mangabeys (SMs) is typically non-pathogenic despite high viremia. Several studies suggested that low immune activation and relative resistance of CD4+ central memory T-cells from virus infection are mechanisms that protect SMs from AIDS. In 2008 it was reported that plasmacytoid dendritic cells (pDCs) of SMs exhibit attenuated interferon-alpha (IFN-α) responses to TLR7/9 ligands in vitro, and that species-specific amino acid substitutions in SM Interferon Regulatory Factor-7 (IRF7) are responsible for this observation. Based on these findings, these authors proposed that "muted" IFN-α responses are responsible for the benign nature of SIV infection in SMs. However, other studies indicated that acutely SIV-infected SMs show robust IFN-α responses and marked upregulation of Interferon Stimulated Genes (ISGs). To investigate this apparent disparity, we first examined the role of the reported IRF7 amino acid substitutions in SMs. To this end, we sequenced all IRF7 exons in 16 breeders, and exons displaying variability (exons 2,3,5,6,7,8) in the remainder of the colony (177 animals). We found that the reported Ser-Gly substitution at position 191 was a sequencing error, and that several of the remaining substitutions represent only minor alleles. In addition, functional assays using recombinant SM IRF7 showed no defect in its ability to translocate in the nucleus and drive transcription from an IFN-α promoter. Furthermore, in vitro stimulation of SM peripheral blood mononuclear cells with either the TLR7 agonist CL097 or SIV(mac239) induced an 500-800-fold induction of IFN-α and IFN-β mRNA, and levels of IFN-α production by pDCs similar to those of RMs or humans. These data establish that IFN-α and IRF7 signaling in SMs are largely intact, with differences with RMs that are minor and unlikely to play any role in the AIDS resistance of SIV-infected SMs.

Indexed as

Active Transport, Cell NucleusAmino Acid SubstitutionAnimalsCell NucleusCercocebus atysDendritic CellsDNA Mutational AnalysisExonsFemaleHIV-1HIV InfectionsHumansImidazolesInterferon-alphaInterferon-betaInterferon Regulatory Factor-7CL097 compoundImidazolesInterferon-alphaInterferon-betaInterferon Regulatory Factor-7QuinolinesRNA, MessengerToll-Like Receptor 7

Identifiers

PMID24009514
PMCPMC3757038
OpenAlexW2004948071

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.